Can lumateperone (Caplyta®) cause metabolic side effects?

This article was published on June 20, 2022. It was last updated on June 23, 2022. Lumateperone (US brand name Caplyta®) is a second-generation (“atypical”) antipsychotic that was approved by the FDA in 2019. For basic information about it, please see the following article on this website: Lumateperone (Caplyta®): Basic information When a new antipsychotic is…